Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.48 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.47 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.46 |
| ▸ | GRM5 | P41594 | 2/20 | 0.46 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.44 |
| ▸ | LCK | P06239 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | F2 | P00734 | 1/20 | 0.43 |
| ▸ | PLG | P00747 | 1/20 | 0.43 |
| ▸ | PLAU | P00749 | 1/20 | 0.43 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.43 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.43 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.42 |
| ▸ | BRAF | P15056 | 3/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4908696 | 0.87 | NPC1 (0.52) | DUSP3LCKKMT2A | |
| SCHEMBL14034418 | 0.84 | LCK (0.46) | LCKKMT2A | |
| SCHEMBL4918817 | 0.84 | LCK (0.46) | LCKKMT2A | |
| SCHEMBL4919320 | 0.84 | EPM2A (0.48) | RXFP1DUSP3GRM5LCKKMT2A | |
| SCHEMBL14006470 | 0.83 | LCK (0.49) | RXFP1LCKKMT2AF2PLG | |
| SCHEMBL14034255 | 0.82 | LCK (0.45) | LCKKMT2A | |
| SCHEMBL4916854 | 0.81 | LCK (0.54) | LCKKMT2A | |
| SCHEMBL4919383 | 0.81 | CCNA2 (0.57) | RXFP1KMT2A | |
| SCHEMBL14006462 | 0.81 | SCD (0.56) | DUSP3LCKKMT2A | |
| SCHEMBL4922841 | 0.81 | CHRM4 (0.56) | RXFP1LCKKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080293785-A1 | SUBSTITUTED BENZOTHIAZOLE KINASE INHIBITORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2008-11-27 | — | — | US | claimed |
| US-20080293785-A1 | SUBSTITUTED BENZOTHIAZOLE KINASE INHIBITORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2008-11-27 | — | — | US | disclosed |
| US-20080293785-A1 | SUBSTITUTED BENZOTHIAZOLE KINASE INHIBITORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2008-11-27 | — | — | US | disclosed |
| US-20080293785-A1 | SUBSTITUTED BENZOTHIAZOLE KINASE INHIBITORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2008-11-27 | — | — | US | disclosed |
| WO-2007121154-A2 | SUBSTITUTED BENZOTHIAZOLE KINASE INHIBITORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-10-25 | — | — | WO | disclosed |
| WO-2007121154-A2 | SUBSTITUTED BENZOTHIAZOLE KINASE INHIBITORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-10-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080293785-A1 | SUBSTITUTED BENZOTHIAZOLE KINASE INHIBITORS | MAP3K20, MAP3K1, MAP3K2 | RXFP1 4152/4885DUSP3 474/4885IRAK4 41/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.